Abstract
MicroRNAs are negative regulators of gene expression that have been shown to be essential elements in the coordination of complex regulatory pathways. One of these short non-coding RNAs, microRNA-126, is highly enriched in the vascular endothelium and was shown to play distinct roles in angiogenesis, vasculogenesis and endothelial inflammation. Abrogation of this microRNA leads to severe complications in the response in vascular development as well as vital repair mechanisms carried out by endothelial cells. Interestingly, recent data suggest that the homeostatic role of microRNA-126 may reach far beyond its endothelial functions as this microRNA was also found to be present in cells of the hematopoietic system and in microvesicles or ‘free-form’ in the periphery. MicroRNA-126 is controlling the fate and/or function of a variety of cells differentiating from the hematopoietic lineage, including megakaryocytes and erythrocytes. Recent studies identified circulating microRNA-126 as a biomarker for myocardial injury and vascular damage in diabetes. Furthermore, reports have suggested a protective role of circulating microRNA-126 in murine models of organ ischemia. Here, we review current insights in the role of microRNA-126 in vascular homeostasis and conclude that this microRNA may serve to integrate and facilitate both local as well as systemic functions in vascular maintenance and repair.
Keywords: Endothelial cells, hematopoietic cells, microRNA-126, microvesicles, platelets, vascular biology.
Current Vascular Pharmacology
Title:The Role of microRNA-126 in Vascular Homeostasis
Volume: 13 Issue: 3
Author(s): Coen van Solingen, Roel Bijkerk, Hetty C. de Boer, Ton J. Rabelink and Anton Jan van Zonneveld
Affiliation:
Keywords: Endothelial cells, hematopoietic cells, microRNA-126, microvesicles, platelets, vascular biology.
Abstract: MicroRNAs are negative regulators of gene expression that have been shown to be essential elements in the coordination of complex regulatory pathways. One of these short non-coding RNAs, microRNA-126, is highly enriched in the vascular endothelium and was shown to play distinct roles in angiogenesis, vasculogenesis and endothelial inflammation. Abrogation of this microRNA leads to severe complications in the response in vascular development as well as vital repair mechanisms carried out by endothelial cells. Interestingly, recent data suggest that the homeostatic role of microRNA-126 may reach far beyond its endothelial functions as this microRNA was also found to be present in cells of the hematopoietic system and in microvesicles or ‘free-form’ in the periphery. MicroRNA-126 is controlling the fate and/or function of a variety of cells differentiating from the hematopoietic lineage, including megakaryocytes and erythrocytes. Recent studies identified circulating microRNA-126 as a biomarker for myocardial injury and vascular damage in diabetes. Furthermore, reports have suggested a protective role of circulating microRNA-126 in murine models of organ ischemia. Here, we review current insights in the role of microRNA-126 in vascular homeostasis and conclude that this microRNA may serve to integrate and facilitate both local as well as systemic functions in vascular maintenance and repair.
Export Options
About this article
Cite this article as:
Solingen van Coen, Bijkerk Roel, de Boer C. Hetty, Rabelink J. Ton and van Zonneveld Jan Anton, The Role of microRNA-126 in Vascular Homeostasis, Current Vascular Pharmacology 2015; 13 (3) . https://dx.doi.org/10.2174/15701611113119990017
DOI https://dx.doi.org/10.2174/15701611113119990017 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Concept of Titration can be Transposed to Fluid Management. But does is Change the Volumes? Randomised Trial on Pleth Variability Index During Fast-Track Colonic Surgery
Current Clinical Pharmacology Inflamm-ageing and senescence in gout: the tale of an old king’s disease.
Current Aging Science Mitochondrial Dysfunctions in Bipolar Disorder: Effect of the Disease and Pharmacotherapy
CNS & Neurological Disorders - Drug Targets Endothelial Dysfunction in the Hypertensive State: Mechanisms of Hypertensive Cardiovascular Complications
Current Hypertension Reviews Endothelial Dysfunction: Methods of Assessment and Application to Hypertension
Current Pharmaceutical Design Remodeling of the Myocardium and Potential Targets in the Collagen Degradation and Synthesis Pathways
Current Drug Targets - Cardiovascular & Hematological Disorders Highlighting Exosomes’ Function in Cardiovascular Diseases
Current Cardiology Reviews Heme Oxygenase-1/CO as Protective Mediators in Cigarette Smoke- Induced Lung Cell Injury and Chronic Obstructive Pulmonary Disease
Current Pharmaceutical Biotechnology Protein Aggregation and Self Assembly in Health and Disease
Current Proteomics FKBP Ligands as Novel Therapeutics for Neurological Disorders
Mini-Reviews in Medicinal Chemistry Oxidative Stress and Endothelial Dysfunction in Cardiovascular Disease: Mitochondria-Targeted Therapeutics
Current Medicinal Chemistry Unconventional Players on the Striated Muscle Field: microRNAs, Signaling Pathways and Epigenetic Regulators
Current Stem Cell Research & Therapy Emerging Role for RBM20 and its Splicing Substrates in Cardiac Function and Heart Failure
Current Pharmaceutical Design Myocardial Perfusion and Coronary Vasomotor Function: Emerging Role of PET Imaging
Vascular Disease Prevention (Discontinued) Health Benefits of Honey: Implications for Treating Cardiovascular Diseases
Current Nutrition & Food Science The Heat Stress Response and Diabetes: More Room for Mitochondrial Implication
Current Pharmaceutical Design Natural Products as Anti-Cancerous Therapeutic Molecules Targeted towards Topoisomerases
Current Protein & Peptide Science Targeting the Toll-System in Cardiovascular Sciences
Recent Patents on Inflammation & Allergy Drug Discovery Cruzipain, the Major Cysteine Protease of Trypanosoma cruzi: A Sulfated Glycoprotein Antigen as Relevant Candidate for Vaccine Development and Drug Target. A Review
Current Medicinal Chemistry Immunopathological Aspects of Mycoplasma pneumoniae Infection
Current Pediatric Reviews